Prevention of ischemia/reperfusion injury by C1 esterase inhibitor (C1 INH): Assessment of reperfusion injury in total knee arthroplasty
| ISRCTN | ISRCTN87180032 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN87180032 |
| Secondary identifying numbers | 201609_DCR_UNIBE_Rieben |
- Submission date
- 24/10/2016
- Registration date
- 04/11/2016
- Last edited
- 12/01/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Knee replacement surgery (arthroplasty) is a routine operation where a damaged, worn or diseased knee is replaced with a new, artificial one. The most common reason for knee replacement surgery is osteoarthritis, but there are others including rheumatoid arthritis, gout, haemophilia, death of bone in the knee following a problem with the blood supply, injury to the knee and diseases that result in unusual bone growth (bone dysplasias). A tourniquet is used for this purpose and leads to the During total knee arthroplasty (TKA – where the entire knee joint is replaced), the blood supply to the knee needs to be stopped (intentional ischemia) in order to do the surgery well and to reduce blood loss during the surgery. Tourniquets are used for this purpose and are applied to stop blood flow to the affected e knee and leg from between 30-120 minutes. It is known that reintroducing blood flow (reperfusion) to an organ or tissue after a prolonged period of ischemia can lead to something called ischemia/reperfusion (I/R) injury. I/R injury is an inflammatory (swelling) reaction of the tissue, probably caused by the presence of ‘danger’ signals on the ischemic endothelium (the inner surface of blood vessels) , which triggers a number of reactions such as the plasma cascades (which causes, for example, blood clots) and also immune system responses. So far, however, the use of a tourniquet in orthopaedic surgery (such as TKA) and how this may lead to I/R injury has not been investigated in detail. In clinical practice, postoperative edema formation (swelling caused by fluid building up in the tissues) in the lower limb (knee and leg) after TKA is often thought to be caused by surgical trauma rather than I/R injury. However, a longer ischemia time in TKA leads to more severe postoperative pain and edema formation, and the link to I/R injury has been made in this study. Previous studies have shown that I/R injury can be reduced if activation of the plasma cascade systems and/or the endothelium is prevented. I/R injury is rats have been prevented by injecting them with a protein called C1-inhibitor before application of the tourniquet. If this could be used for patients, they may benefit from reduced inflammation, including pain and edema formation.
With this in mind, this study is looking at how activation of the endothelium and the plasma cascades in I/R injury after TKA occurs in order to help design a possible study testing C1-inhibitor in the future.
Who can participate?
Adults that are about to have a total knee replacement
What does the study involve?
All patients have total knee replacement surgery. In line with standard practice, some patients have the procedure done with a short period of intentional ischemia using a tourniquet (less than 30 minutes). Other patients will have the procedure done with a longer period of intentional ischemia using a tourniquet (90-120 minutes). All patients are followed up for 48 hours after their surgery to check for evidence of edema and how much morphine is required to relieve pain. Blood sample are taken to look for evidence of coagulation (blood clotting), inflammation and immune system responses.
What are the possible benefits and risks of participating?
There is no direct benefit or risk for the patient because it is an observational study.
Where is the study run from?
Orthopaedic department, University Hospital Bern (Switzerland))
When is the study starting and how long is it expected to run for?
December 2016 to December 2018
Who is funding the study?
CSL Behring AG(Switzerland)
Who is the main contact?
Professor Robert Rieben
robert.rieben@dbmr.unibe.ch
Contact information
Scientific
Department for Biomedical Research (DBMR)
Murtenstrasse 24
Bern
3008
Switzerland
 ORCID ID |
0000-0003-4179-8891 |
|---|---|
| Phone | +41 31 684 04 91 |
| robert.rieben@dbmr.unibe.ch |
Study information
| Study design | Single centre observational case-control study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Case-control study |
| Study setting(s) | Hospital |
| Study type | Diagnostic |
| Scientific title | Prevention of ischemia/reperfusion injury by C1 INH. Assessment of reperfusion injury in total knee arthroplasty: pilot study |
| Study objectives | Total knee arthroplasty can be associated post operatively with edema formation and pain due to ischemia reperfusion (I/R) injury. I/R injury usually develops due to the use of a tourniquet to provide a bloodless surgical field. The exact mechanisms are still not known but the activation of the complement system leads to the development of an inflammatory response that ends with edema and pain. The current study is a pilot study to diagnose the occurrence of reperfusion injury after both short and long tourniquet time. |
| Ethics approval(s) | Kantonale Ethikkommisson for die Forschung (KEK Bern), 27/07/2017, ref: 2017-00217 |
| Health condition(s) or problem(s) studied | Ischemia reperfusion injury after total knee arthroplasty |
| Intervention | Total knee arthroplasty is an elective surgical procedure that takes place when medication and/or walking support instruments can no longer relieve severe knee pain. Using a tourniquet is important to produce a bloodless surgical field but in the same time it causes ischemia to the leg. Both modalities (ischemia less than 30 minutes or ischemia up to 120 minutes) are a standard surgical procedure. The procedure can be done either with a short (less than 30 minutes) or long (90-120 minutes) period of ischemia using a tourniquet - both are standard clinical procedures. This study will compare these two procedures. The patients will be followed up for 48 hours after the surgery as followed (0, 4, 24 and 48 hours postoperative). Following up criteria are: 1. Calf circumference 15 cm below knee joint to assess ‘edema’, important clinical outcome to assess ischemia reperfusion injury 2. Amount of morphine intake to assess postoperative pain level 3. Blood samples to measure different complement, coagulation and inflammatory markers |
| Intervention type | Procedure/Surgery |
| Primary outcome measure | Shorter tourniquet time – less expected edema of the calf muscle: Measurement of calf circumference 15 cm below knee joint before operation, immediately post OP, 4h, 24h and 48h post operative. |
| Secondary outcome measures | 1. Plasma levels of CK-MM for muscle damage using an ELISA Kit 2. Plasma levels of pro-inflammatory cytokines and markers of the activation of the plasma cascade systems as well as the endothelium using different commercial available kits for each marker 3. Postoperative pain levels as assessed by postoperative use of analgesic (morphine). Assessment of the amount of morphine needed All outcomes assessed at 0, 4, 24 and 48 hours after surgery |
| Overall study start date | 01/12/2016 |
| Completion date | 31/12/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 90 Years |
| Sex | Both |
| Target number of participants | 60 patients |
| Total final enrolment | 40 |
| Key inclusion criteria | 1. Adults aged 18-90 2. Scheduled for elective total knee arthroplasty |
| Key exclusion criteria | 1. Conditions which are known to influence edema formation 2. Trauma 3. Infections |
| Date of first enrolment | 01/01/2017 |
| Date of final enrolment | 31/08/2020 |
Locations
Countries of recruitment
- Switzerland
Study participating centre
Freiburgstrasse 8
Bern
3010
Switzerland
Sponsor information
University/education
Department of Clinical Research
Murtenstrasse 50
Bern
3008
Switzerland
| Phone | +41 31 632 96 69 |
|---|---|
| robert.rieben@dkf.unibe.ch | |
"ROR" |
https://ror.org/02k7v4d05 |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 31/12/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The current data sharing plans for the current study are unknown and will be made available at a later date |
Editorial Notes
12/01/2022: The following changes were made to the trial record:
1. The intention to publish date was changed from 31/12/2021 to 31/12/2022.
2. The total final enrolment was added.
3. The contact details were updated.
06/09/2018: The following changes were made to the trial record:
1. The recruitment end date was changed from 31/07/2018 to 31/08/2020.
2. The overall trial end date was changed from 31/12/2018 to 31/12/2020.
3. The intention to publish date was changed from 31/12/2018 to 31/12/2021.
19/01/2018: The recruitment end date has been updated from 31/12/2017 to 31/07/2018 . The overall trial end date has been updated from 31/07/2018 to 31/12/2018.
05/09/2017: Ethics approval information has been added. Publication and dissemination plan and individual patient data sharing statement have been added.
